In a patient with a lipid panel showing total cholesterol 321 mg/dL, triglycerides 225 mg/dL, HDL 30 mg/dL, and LDL 155 mg/dL, which medication is first-line for lipid management?

Prepare effectively for the Physician Assistant Clinical Knowledge Rating and Assessment Tool (PACKRAT) 1 Exam with comprehensive resources, flashcards, and detailed explanations. Ace your test with ease!

Multiple Choice

In a patient with a lipid panel showing total cholesterol 321 mg/dL, triglycerides 225 mg/dL, HDL 30 mg/dL, and LDL 155 mg/dL, which medication is first-line for lipid management?

Explanation:
Starting therapy with a statin is the best approach because statins directly lower LDL cholesterol and have the strongest evidence for reducing cardiovascular risk. They work by inhibiting HMG-CoA reductase, the enzyme that makes cholesterol in the liver, which triggers the liver to upregulate LDL receptors and pull more LDL out of the bloodstream. In this patient, the LDL is elevated at 155 mg/dL and total cholesterol is high, so lowering LDL takes priority, and a statin like simvastatin provides the most robust, guideline-supported benefit. Other options either target different parts of the lipid profile or have less impact on LDL or more tolerability concerns. Cholestyramine can lower LDL but is less favored due to palatability and adherence issues. Niacin and fibrates mainly affect triglycerides and HDL and carry side effects or interactions that aren’t ideal as first-line for isolated LDL elevation.

Starting therapy with a statin is the best approach because statins directly lower LDL cholesterol and have the strongest evidence for reducing cardiovascular risk. They work by inhibiting HMG-CoA reductase, the enzyme that makes cholesterol in the liver, which triggers the liver to upregulate LDL receptors and pull more LDL out of the bloodstream. In this patient, the LDL is elevated at 155 mg/dL and total cholesterol is high, so lowering LDL takes priority, and a statin like simvastatin provides the most robust, guideline-supported benefit.

Other options either target different parts of the lipid profile or have less impact on LDL or more tolerability concerns. Cholestyramine can lower LDL but is less favored due to palatability and adherence issues. Niacin and fibrates mainly affect triglycerides and HDL and carry side effects or interactions that aren’t ideal as first-line for isolated LDL elevation.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy